La Ongsri AtchaneeyasakulAdisak TrinavaratParapun BumrungsukWarapat WongsawadMahidol University2018-06-212018-06-212005-05-01Japanese Journal of Ophthalmology. Vol.49, No.3 (2005), 211-215002151552-s2.0-21144437718https://repository.li.mahidol.ac.th/handle/20.500.14594/16981Purpose: To assess the role of serum anticardiolipin IgG antibody and fasting plasma homocysteine levels as risk factors for retinal vascular occlusive disease in Thai patients. Methods: This is a retrospective, case-control study. Forty-one consecutive patients with recent onset of retinal vascular occlusive diseases were enrolled. In conjunction with a routine laboratory work up, serum anticardiolipin IgG antibody and plasma homocysteine were evaluated. Ninety volunteers without a history of retinal vascular occlusive disease were chosen as controls. Results: In general, mean levels of anticardiolipin IgG antibody and homocysteine did not differ between the patients and controls. However, when the groups without a history of underlying systemic diseases were compared, there were statistically significant differences in the anticardiolipin IgG antibody level between patients and controls (mean 12.24 ± 8.66 and 7.70 ± 6.69 GPL units/ml, respectively) with a P value of 0.024. Conclusions: No association was found between plasma homocysteine level and retinal vascular occlusion in our patient population. A high level of anticardiolipin IgG antibody is shown to be a risk factor only in patients without a history of underlying systemic diseases. The effect of anticardiolipin IgG antibody on the development of retinal vascular occlusive disease appears to be limited and may not be a major cause. © Japanese Ophthalmological Society 2005.Mahidol UniversityMedicineArticleSCOPUS10.1007/s10384-005-0190-3